前立腺がんにおけるLKB1の役割:腫瘍の進行と治療への影響
PubMedで要約を見る
まとめ
この要約は機械生成です。前立腺がんにおける肝キナーゼB1 (LKB1) の喪失は,重要な経路を阻害することで,代謝変化と治療抵抗を誘発する. これらの代謝と表遺伝的特徴をターゲットにすることで 精密医療の新たな戦略が生まれます
科学分野
- 腫瘍学
- 分子生物学
- 癌 代謝
背景
- 肝臓キナーゼB1 (LKB1/STK11) は前立腺がん (PCa) の重要な腫瘍抑制剤である.
- LKB1は細胞の代謝,表遺伝子,信号伝達経路を調節する.
- LKB1の喪失は,代謝の再プログラム,血統の可塑性,およびPCaにおける治療耐性に関連しています.
研究 の 目的
- 前立腺がんにおけるLKB1中心のネットワークを 検討する.
- LKB1の不活性化と エピジェネティック・リモデリングと アグレッシブな腫瘍のフェノタイプとの関係を強調する
- LKB1欠乏症のPCaの治療戦略について議論する.
主な方法
- PCaにおけるLKB1に関する現在の証拠の文献レビュー.
- 代謝再プログラムとシグナル伝達経路 (AMPK/mTOR,STAT3,Hh) に関するLKB1の役割の分析
- LKB1/PTEN共損失が腫瘍の分化に及ぼす影響の検討
主要な成果
- LKB1の喪失はAMPK/mTOR,STAT3,およびHh経路を調節し,PCaの進行を促します.
- LKB1の不活性化は表遺伝的変異と攻撃的な腫瘍現象と相関しています.
- LKB1とPTENの喪失は,腫瘍の分化に大きく影響する.
結論
- LKB1欠乏症のPCaは,異なった代謝および表遺伝的脆弱性を表しています.
- 精密医療によって これらの脆弱性を ターゲットにすることで 患者の治療結果を 改善する見込みがあります
- LKB1欠乏症のPCaにおける治療抵抗性の対処には,バイオマーカー主導の戦略が不可欠である.
関連する概念動画
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Three of the best-understood negative regulators are p53, p21, and retinoblastoma protein (Rb). The regulatory roles of each of these proteins were discovered after faulty copies were found in cells with uncontrolled replication (i.e.,...

